Publications

Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era.
Cancer Epidemiol Biomarkers Prev 2014 Apr 12;23(4):670-4. Epub 2014 Feb 12.
Authors' Affiliations: Genomic Epidemiology Group, Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Hematology, Cracow University Hospital, Cracow; Medical University of Łodz; Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; Rzeszow Regional Hospital, Rzeszow; Holycross Cancer Center, Kielce, Poland; Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; Morales Meseguer General University Hospital, Murcia; University Hospital of Salamanca, Salamanca; Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; Hematology Department, Virgen de las Nieves University Hospital, Granada; IDIBELL-Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; Semmelweis University, Budapest, Hungary; Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; Department of Biology, University of Pisa, Pisa, Italy; Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; Organ Center, Hospital of Southern Jutland, Aabenraa; Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; National Research Centre for the Working Environment, Copenhagen; Roskilde Hospital, Copenhagen University, Roskilde, Denmark; Life and Health Sciences Research Institute, University of Minho, Braga; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.



OF